{
    "clinical_study": {
        "@rank": "131140", 
        "arm_group": [
            {
                "arm_group_label": "ASP015K Test Tablet - Fasting Conditions", 
                "arm_group_type": "Experimental", 
                "description": "ASP015K administered as a single tablet under fasting conditions."
            }, 
            {
                "arm_group_label": "ASP015K Reference Tablet - Fasting Conditions", 
                "arm_group_type": "Experimental", 
                "description": "ASP015K administered via multiple tablets under fasting conditions"
            }, 
            {
                "arm_group_label": "ASP015K Test Tablet -Fed Conditions", 
                "arm_group_type": "Experimental", 
                "description": "ASP015K administered as a single tablet under fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the relative bioavailability of ASP015K under\n      fasting conditions after single-dose administration between a test-tablet formulation and a\n      reference-tablet formulation. This study will also evaluate the food effect on\n      bioavailability of the test formulation, and evaluate the safety and tolerability after\n      single-dose administration of the test- and reference-tablet formulations."
        }, 
        "brief_title": "A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Bioavailability of ASP015K", 
            "Healthy Subjects", 
            "Pharmacokinetics of ASP015K", 
            "Food Effect of ASP015K"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female subject must be of non-childbearing potential (i.e., post-menopausal [defined\n             as at least 1 year without menses prior to screening], or documented surgically\n             sterile or status post hysterectomy [at least 1 month prior to screening]).\n\n          -  Female subject must have a negative pregnancy test at screening and day -1 of\n             treatment period 1.\n\n          -  Female subject must not donate ova starting at screening and throughout the study\n             period, and for 90 days after the final study drug administration.\n\n          -  Male subject and his female spouse/partner who is of childbearing potential must be\n             using highly effective contraception consisting of two forms of birth control (one of\n             which must be a barrier method) starting at screening and continue throughout the\n             study period and for 90 days after final study drug administration.\n\n          -  Male subject must not donate sperm starting at screening and throughout the study\n             period and for 90 days after final study drug administration.\n\n          -  Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must\n             weigh at least 50 kg at screening.\n\n        Exclusion Criteria:\n\n          -  Female subject who has been pregnant within 6 months before screening assessment or\n             breast feeding within 3 months before screening.\n\n          -  Subject has a known or suspected hypersensitivity to ASP015K, or any components of\n             the formulation used.\n\n          -  Subject has any clinically significant history of allergic conditions (including drug\n             allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated,\n             asymptomatic, seasonal allergies at time of dosing).\n\n          -  Subject has/had febrile illness or symptomatic, viral, bacterial (including upper\n             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to\n             first clinic check-in.\n\n          -  Subject has used any prescribed or non-prescribed drugs (including vitamins, natural\n             and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug\n             administration, with the exception of hormone replacement therapy (HRT), intermittent\n             acetaminophen (to a maximum of 2 g/day).\n\n          -  Subject has smoked or has used tobacco-containing products and nicotine or\n             nicotine-containing products in the past six months prior to screening.\n\n          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week\n             within 6 months prior to screening or has a history of alcoholism or drug/chemical\n             substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of\n             beer, 4 ounces of wine or 1 ounce of spirits) prior to day -1 of treatment period 1.\n\n          -  Subject has had any significant blood loss, donated one unit (450 mL) of blood or\n             more, or received a transfusion of any blood or blood products within 60 days or\n             donated plasma within 7 days prior to clinic check-in on day -1 of treatment period\n             1.\n\n          -  Subject has a positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis A\n             virus (HAV) (Immunoglobulin [Ig] M), anti-hepatitis C virus (HCV), hepatitis B core\n             antibody, or anti-human immunodeficiency virus (HIV) type 1 or type 2 at screening.\n\n          -  Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold\u00ae test or T-SPOT\u00ae\n             test at screening.\n\n          -  Subject received any vaccine within 60 days prior to study drug administration.\n\n          -  Subject has an absolute neutrophil count (ANC) < 2000 cells/mm3 or a creatine\n             phosphokinase (CPK) > 1.5 x ULN at screening or day -1 of treatment period 1.\n\n          -  Subject has had major gastrointestinal (GI) surgery or has a medical condition, which\n             may inhibit the absorption and/or metabolism of study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929577", 
            "org_study_id": "015K-CL-PK09"
        }, 
        "intervention": {
            "arm_group_label": [
                "ASP015K Test Tablet - Fasting Conditions", 
                "ASP015K Reference Tablet - Fasting Conditions", 
                "ASP015K Test Tablet -Fed Conditions"
            ], 
            "description": "oral tablet", 
            "intervention_name": "ASP015K", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ASP015K", 
            "healthy subjects"
        ], 
        "lastchanged_date": "September 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "Parexel - Early Phase Clinical Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Between Two ASP015K Tablet Formulations and the Food Effect on a New Tablet Formulation in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum Concentration (Cmax)", 
                "measure": "Pharmacokinetic parameter of ASP015K: Cmax", 
                "safety_issue": "No", 
                "time_frame": "Day 1-4 of each treatment period"
            }, 
            {
                "description": "Area Under the Curve from time zero to the last measurable time (AUClast)", 
                "measure": "Pharmacokinetic parameter of ASP015K: AUClast", 
                "safety_issue": "No", 
                "time_frame": "Day 1-4 of each treatment period"
            }, 
            {
                "description": "Area Under the Curve from time zero extrapolated to infinity (AUCinf)", 
                "measure": "Pharmacokinetic parameter of ASP015K: AUCinf", 
                "safety_issue": "No", 
                "time_frame": "Day 1-4 of each treatment period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929577"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to Maximum Concentration (tmax), apparent terminal elimination half-life (t1/2)", 
                "measure": "Composite of pharmacokinetic parameters of ASP015K: tmax, t1/2", 
                "safety_issue": "No", 
                "time_frame": "Day 1-4 of each treatment period"
            }, 
            {
                "measure": "Composite of pharmacokinetic parameters of ASP015K metabolites: Cmax, AUClast, AUCinf, tmax, t1/2", 
                "safety_issue": "No", 
                "time_frame": "Day 1-4 of each treatment period"
            }, 
            {
                "measure": "Safety assessed by adverse events, clinical laboratory evaluations, 12-lead ECG measurements, physical examinations and vital sign measurements", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 4 in each treatment period"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Biotech, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}